Biologics Quality Control Testing
ABOUT US
PathoQuest, a spin-out of Institut Pasteur Paris, is a genomics expert company offering a game-changing next-generation sequencing (NGS) approach for microbiology testing.
The NGS-based technology the company has developed is used for:
• The quality control (QC) testing of biologicals (e.g., ATMP, vaccines, antibodies), enabling rapid and robust analysis at a GMP level
PathoQuest’s technology leverages the company’s proprietary sample preparation protocols, which are applicable to several types of biological samples, proprietary internally-curated pathogen genome databases, and automated analysis pipelines.
LATEST NEWS
They talk about us: Staying abreast of regulations with NGS-based viral safety for faster, safer and more ethical lot release of vaccines.
In this European Pharmaceutical Review article, Sridhar Pennathur, Vice President, Analytical Development at Novavax, highlights the value of next generation sequencing in their vaccine production operations by answering key questions.
PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer
PathoQuest announced the appointment of Michael Mellor-Clark as company CCO. Michael Mellor-Clark has more than 20 years of commercial experience in biosafety testing services
PathoQuest to Participate in PDA Virus Conference – Brussels, Belgium | 20-21 June 2022
Changing landscape of viral safet for existing and advanced technologies is a common target for the industry.
The overall program is designed to provide an update on regulatory expectations and the scientific framework around the virus safety of plasma-derived and biotechnology medicinal products, as well as particularly innovative cell- and gene therapies.
Let’s Start Something New
Welcome to PathoQuest!
